Journal of Neuro-Oncology

, Volume 19, Issue 2, pp 137–147 | Cite as

Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats

  • Michael G. Kaplitt
  • Juri G. Tjuvajev
  • David A. Leib
  • Jeffrey Berk
  • Karen D. Pettigrew
  • Jerome B. Posner
  • Donald W. Pfaff
  • Samuel D. Rabkin
  • Ronald G. Blasberg
Laboratory Investigation


Herpes simplex virus (HSV) mutants kill dividing tumor cells but spare non-proliferating, healthy brain tissue and may be useful in developing new treatment strategies for malignant brain tumors. Two HSV mutants, a thymidine kinase deficient virus (TK-) and a ribonucleotide reductase mutant (RR-), killed 7/7 human tumor cell lines in tissue culture. The TK-HSV killed Rat RG2 glioma and W256 carcinoma lines but not the rat C6 glioma in culture. TK-HSV replication (12 pfu/cell) was similar to wild-type HSV (10 pfu/cell) in rapidly dividing W256 cells in tissue culture, but was minimal (<1 pfu/cell) in serum-starved cells, suggesting that the proliferative activity of tumor cells at the site and time of TK-HSV injection may influence efficacyin vivo. Subcutaneous W256 tumors in male Sprague-Dawley rats were injected with TK-HSV or virus free inoculum. A significant effect of TK-HSV therapy on W256 tumor growth was demonstrated compared to controls (p=0.002). Complete regression was observed in 4/9 experimental tumors, with no recurrence over 6 months. Tumor growth in the remaining 5/9 animals was attenuated during the first 3 to 5 days after treatment, but not beyond 5 days compared to 9 matched control animals; no tumor regression was observed in any of the control animals. These results suggest that HSV mutants are potentially useful as novel therapeutic agents in the treatment of tumors in immunocompetent subjects.

Key words

HSV thymidine kinase ribonucleotide reductase viral vector anti-tumor effect 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Committee on Health Care Issues, American Neurological Association: Chemotherapy for malignant gliomas. Ann Neurol 25: 88–89Google Scholar
  2. 2.
    Stewart DJ: The role of chemotherapy in the treatment of gliomas in adults. Canc Treat Rev 16: 129–160, 1989Google Scholar
  3. 3.
    Walker MD, Green SB, Byar DP, Alexander E, Batzdorf U, Brooks WHet al.: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant gliomas after surgery. New Eng J of Med 303: 1323–1329, 1978Google Scholar
  4. 4.
    Cassel WA, Murray DR, Phillips HS: A phase II study on the postsurgical management of stage II malignant melanoma with a Newcastle disease virus oncolysate. Cancer 52: 856–860, 1983Google Scholar
  5. 5.
    Taylor MW, Cordell B, Southrada M, Prather S: Viruses as an aid to cancer therapy: regression of solid and ascites tumors in rodents after treatment with bovine enterovirus. Proc Natl Acad Sci USA 68: 836–840, 1971Google Scholar
  6. 6.
    Sharpless NE, O'Brien WA, Verdin E, Kufta CV, Chen ISY, Dubois-Dalcq M: Human immunodeficiency virus type 1 tropsim for brain microglial cells is determined by a region of the env glycoprotein that also controls macrophage tropism. J Virol 66: 2588–2593, 1992Google Scholar
  7. 7.
    Dulbecco R, Ginsberg HS: Virology. Harper and Row, Philadelphia, 1980Google Scholar
  8. 8.
    Roizman B, Batterson W: The replication of herpes viruses. In: Fields B (ed.) General Virology, pp 497–526. Raven Press, New York, 1984Google Scholar
  9. 9.
    Wagner EK: In: Roizman B (ed.) The Herpes viruses. New York, Plenum Press: 288–321, 1985Google Scholar
  10. 10.
    Dubbs DR, Kit S: Mutant strains of herpes simplex deficient in thymidine kinase-induced activity. Virology 22: 493–502, 1964Google Scholar
  11. 11.
    Goldstein DJ, Weller SK: Herpes simplex virus type-1 induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 62: 196–205, 1988Google Scholar
  12. 12.
    McGeoch DJ, Weller SK, Schaffer PA: Genetic Maps. CSHL Press: 1.115–1.120,1990Google Scholar
  13. 13.
    Jamieson AT, Gentry GA, Subak-Sharpe JH: Induction of both thymidine and deoxytidine kinase activity by herpes simplex virus. J Gen Virol 24: 465–480, 1974Google Scholar
  14. 14.
    Engstrom Y, Rozell B, Hansson HA, Stemme S, Thelander L: Localization of ribonucleotide reductase in mammalian cells. EMBO J 3: 863–867, 1984Google Scholar
  15. 15.
    Field HJ, Darby G: Pathogenicity in mice of strains of herpes simplex virus which are resistant to acyclovirin vitro andin vivo. Animicrob Agent Chemother 17: 209–216, 1980Google Scholar
  16. 16.
    Thelander C, Reichard P: Reduction of ribonucleotides. Ann Rev Biochem 48: 133–158, 1979Google Scholar
  17. 17.
    Cowan M, Davies J, Brookes K, Billstrom M, McLeish P, Buchan A, Skinner GR: Inhibition of rate of tumor growth in rodent species by inoculation of herpes viruses and encephalomyocarditis virus. J Med Virol 30: 211–215, 1990Google Scholar
  18. 18.
    Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM: Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252: 854–855, 1991Google Scholar
  19. 19.
    Coen DM, Kosz-Vnenchak M, Jacobson JG, Leib DA, Bogard CL, Schaffer PA, Tyler KL, Knipe DM: Thymidine kinase negative herpesvirus mutants establish latency in mouse trigeminal ganglia, but do not reactivate. Proc Nat Acad Sci 86: 4736–4740, 1989Google Scholar
  20. 20.
    DeLuca NA, Courtney MA, Schaffer PA: Temperature sensitive mutants in HSV-1 ICP4 permissive for early gene expression. J Virol 52: 767–776, 1984Google Scholar
  21. 21.
    Kaplitt MG, Pfaus JG, Kleopoulos SP, Hanlon BA, Rabkin SD, Pfaff DW: Expression of a functional foreign gene in adult mammalian brain followingin vivo transfer via a herpes simplex virus type 1 defective viral vector. Mol Cell Neurosci 2: 320–330, 1991Google Scholar
  22. 22.
    Blasberg RG, Groothuis D, Molnar P: Application of quantitative autoradiographic measurements in experimental brain tumor models. Semin Neurol 1: 203–223, 1981Google Scholar
  23. 23.
    Blasberg RG, Shapiro WR, Molnar R, Patlak CS, Fenstermacher JD: Local blood flow in Walker 256 metastatic brain tumors. J Neuro-Oncol 2: 195–204, 1984Google Scholar
  24. 24.
    Hoshino T, Nagashima T, Murovic J, Wilson CB, Edwards MSB, Gutin PH, Davis RL, DeArmond SJ:in situ cell kinetics studies on human neuroectodermal tumors with bromodeoxyuridine labeling. J Neurosurg 64: 453–459, 1986Google Scholar
  25. 25.
    Jacobson JG, Leib DA, Goldstein DJ, Bogard CL, Schaffer PA, Weller SK, Coen DM: A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivalable latent infection of mice and for replication in mouse cells. Virology 173: 276–283, 1989Google Scholar
  26. 26.
    Turk SR, Kik NA, Birch GM, Chiego DJ, Shipman C: Herpes simplex virus type 1 ribonucleotide reductase null mutants induce lesions in guinea pigs. Virology 173: 733–735, 1989Google Scholar
  27. 27.
    Bagshaw M, Doggett R, Smith K, Kaplan H, Nelsen T: Intraarterial 5-bromodeoxyuridine and X-ray therapy. Radiology 99: 886–894, 1967Google Scholar
  28. 28.
    Hoshino T, Prados M, Wilson C, Cho K, Lee K, Davis R: Prognostic implications of the bromodeoxyuridine labeling index of human gliomas. J Neurosurg 71: 335–341, 1989Google Scholar
  29. 29.
    Hoshino T, Rodriguez L, Cho K, Lee KS, Wilson CB, Edwards MS, Levin VA, Davis RL: Prognostic implications of the proliferative potential of low-grade astrocytomas. J Neurosurg 69: 839–842, 1988Google Scholar
  30. 30.
    Bresnik E, Thompson VB: Properties of deoxythymidine kinase partially purified from animal tumors. J Biol Chem 240: 3967, 1965Google Scholar
  31. 31.
    Kit S, Dubbs D: Properties of deoxythymidine kinase partially purified from non-infected and virus-infected mouse fibroblast cells. Virology 26: 16–27, 1965Google Scholar
  32. 32.
    Voytek P, Chang PK, Prusoff W: Purification of deoxythymidine kinase by preparative disk gel electrophoresis and the effects of various halogenated nucleoside triphosphates on its enzymatic activity. J Biol Chem 246: 1432–1438, 1971Google Scholar
  33. 33.
    Roszman T, Elliott L, Brooks W: Modulation of t-cell function by gliomas. Immunology Today 12(10): 370–374, 1991Google Scholar
  34. 34.
    Kuppner MC, Hamou MF, Tribolet N: Activation and adhesion molecule expression on lymphoid infiltrates in human glioblastomas. J of Neuroimmunology 29: 229–238, 1990Google Scholar
  35. 35.
    Sawamura Y, Abe H, Aida T, Hosokawa M, Kobayashi H: Isolation andin vitro growth of glioma-infiltrating lymphocytes, and an analysis of their surface phenotypes. J Neurosurg 69: 745–750, 1988Google Scholar
  36. 36.
    Corey L, Spear PG: Infections with herpes simplex viruses. N Eng J of Med 314: 686–691, 1986Google Scholar
  37. 37.
    Roizman B, Jenkins FJ: Genetic engineering of novel genomes of large DNA viruses. Science 229: 1208–1214, 1985Google Scholar
  38. 38.
    Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM:In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256: 1550–1552, 1992Google Scholar
  39. 39.
    Ezzedine ZD, Martuza RL, Platika D, Short MP, Malick A, Choi B, Breakefield XO: Selective killing of glioma cells in culture andin vivo by retrovirus transfer for the herpes simplex virus thymidine kinase gene. New Biol 3: 608–614, 1991Google Scholar
  40. 40.
    Challberg MD, Kelly TJ: Animal virus DNA replication. Annu Rev biochem 58: 671–717, 1989Google Scholar
  41. 41.
    Gray DA: Insertional mutagenesis: neoplasia arising from retroviral integration. Cancer Invest 9: 295–304, 1991Google Scholar
  42. 42.
    Gilboa E: Retrovirus vectors and their uses in molecular biology. BioEssays 5: 252–257, 1987Google Scholar
  43. 43.
    Miller DG, Adam MA, Miller AD: Gene transfer by retro-virus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 10: 4239–4242, 1990Google Scholar
  44. 44.
    Hoshino T, Barker M, Wilson CB, Boldrey EB, Fewer D: Cell kinetics of human gliomas. J Neurosurg 37: 15–26, 1972Google Scholar

Copyright information

© Kluwer Academic Publishers 1994

Authors and Affiliations

  • Michael G. Kaplitt
    • 1
  • Juri G. Tjuvajev
    • 2
  • David A. Leib
    • 4
  • Jeffrey Berk
    • 2
  • Karen D. Pettigrew
    • 5
  • Jerome B. Posner
    • 2
  • Donald W. Pfaff
    • 1
  • Samuel D. Rabkin
    • 3
  • Ronald G. Blasberg
    • 2
  1. 1.Laboratory of Neurobiology and BehaviorRockefeller UniversityNew York
  2. 2.Department of NeurologyMemorial Sloan Kettering Cancer CenterNew York
  3. 3.Program in Molecular BiologyMemorial Sloan Kettering Cancer CenterNew York
  4. 4.Department of Ophthalmology and Visual SciencesWashington University School of MedicineSt. Louis
  5. 5.Division of Applied and Services ResearchNational Institute of Mental HealthBethesda

Personalised recommendations